₹ 325 a dose, and for ₹ 800 in private settings. It is country’s first indigenously made nasal Covid-19 vaccine. In December, iNCOVACC received approval for a primary two-dose schedule, and as a heterologous booster dose.Clinical trials were conducted to evaluate iNCOVACC as a primary dose, and as heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid-19 vaccines in India.
The vaccine has been developed in partnership with Washington University St Louis, which designed and developed and evaluated it in preclinical studies for efficacy.
Product development related to preclinical safety evaluation, large-scale manufacturing scale-up, formulation and delivery device development, including human clinical trials were conducted by Bharat Biotech.
The product development and clinical trials were funded in part by the Centre. iNCOVACC has been made available on the CoWin platform. “With the rollout of iNCOVACC today, we have achieved our goal of establishing novel vaccine delivery platform for intranasal delivery.